196 related articles for article (PubMed ID: 15735815)
1. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
Schousboe JT; Brown GA
J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
[TBL] [Abstract][Full Text] [Related]
4. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
Gould MK; Dembitzer AD; Sanders GD; Garber AM
Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
[TBL] [Abstract][Full Text] [Related]
8. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Chest; 2005 Sep; 128(3):1601-10. PubMed ID: 16162764
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Seaman CD; Smith KJ; Ragni MV
Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
[TBL] [Abstract][Full Text] [Related]
13. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
15. Routine Use of Low-Molecular-Weight Heparin For Deep Venous Thrombosis Prophylaxis After Foot and Ankle Surgery: A Cost-Effectiveness Analysis.
Robinson R; Wirt TC; Barbosa C; Amidi A; Chen S; Joseph RM; Fleischer AE
J Foot Ankle Surg; 2018; 57(3):543-551. PubMed ID: 29685566
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
Connell NT; Abel GA; Connors JM
Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
[TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
Aujesky D; Smith KJ; Roberts MS
Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
[TBL] [Abstract][Full Text] [Related]
18. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
19. Cost considerations surrounding current and future anticoagulant therapies.
Fang MC; Minichiello T; Auerbach AD
Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S43-9. PubMed ID: 15853179
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
